Abstract:Abstract BACKGROUND AND AIMS Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease. It is caused by mutations in the PKD1 gene, and to a lesser extent PKD2. In this context, accumulating evidence has suggested a potential role of reduced AMP-activated protein kinase (AMPK) signaling in modulating cyst growth. We assessed the potential effects of PXL770, a clinical stage direct allosteric AMPK activator in conventional ADPKD models—3D cyst growth/swelling in vitro and efficacy in an ADPKD mouse model. METHOD In vitro, PXL770 (0.5–50 μM) was tested in 3D cyst assays using: (i) principal-like Madin-Darby Canine Kidney cells (plMDCK) activated by forskolin 10 μM and (ii) ADPKD patient-derived primary cells activated by desmopressin 2.5 μM. In both assays AMPK activation was also assessed by western blotting. In vivo, a kidney specific P18 tamoxifen induced Pkd1 KO mouse model (KspCad-CreERT2, Pkd1lox, lox—‘ADPKD mice’ [Lantinga-van Leeuwen IS, Hum Mol Genet 2007]) was used. Following Pkd1 inactivation at age 18–20 days, mice (n = 22 per group) received PXL770 75 mg/kg by oral gavage twice daily from 42 to 103 days old of age. Mice were treated until 50% of the untreated ADPKD group showed renal failure (blood urea level ≥20 mmol/L). Kidney weight and kidney histology were evaluated. RESULTS In plMDCK cysts, PXL770 dose dependently reduced cyst growth induced by forskolin by 30%, 65% and 82% at 10, 25 and 50 μM, respectively, compared with untreated control cysts (P < 0.05). These results were confirmed in human cysts where PXL770 inhibited desmopressin induced cyst swelling measured by cyst area, −67% at 15 μM compared with untreated control cysts (P < 0.001), and −115% at 50 μM (P < 0.0001)—below cyst area observed in solvent unstimulated condition. Similar result was achieved with tolvaptan. PXL770-mediated AMPK activation was confirmed in both cyst assay systems. Untreated ADPKD mice exhibited a significantly elevated level of blood urea compared with wild-type mice (+105%, P < 0.01). The blood urea level was lowered in PXL770-treated mice compared with untreated animals (−47%, P < 0.01). PXL770 significantly reduced total kidney weight (−29%, P < 0.01) and total kidney to body weight ratio (−35%, P < 0.01) compared with untreated ADPKD mice, without modifying the body weight. Untreated ADPKD mice demonstrated extensive renal epithelial cyst formation, with a cystic area and a cystic index of 9.4 mm2 and 33%, respectively. In PXL770-treated ADPKD mice, the mean cystic area and the cystic index were lowered to 7.1 mm2 and 28%, respectively. CONCLUSION Direct AMPK activation with PXL770 strongly reduced cyst growth and swelling in vitro in canine and human models and was shown to produce considerable efficacy in an orthologous genetic mouse model of ADPKD. These results show the potential of direct allosteric AMPK activation in ADPKD and support the further development of PXL770 in this indication.

405-P: Pharmacological Activation of Kidney AMPK Promotes Diuresis and Natriuresis in Rats

Pan AMPK Activation Protects Tubules in Rat Ischemic Acute Kidney Injury

Pharmacological Melanocortin 5 Receptor Activation Attenuates Glomerular Injury and Proteinuria in Rats with Puromycin Aminonucleoside Nephrosis.

Atrial Natriuretic Peptide Stimulates Dopamine Tubular Transport by Organic Cation Transporters: A Novel Mechanism to Enhance Renal Sodium Excretion

Ampk Potentiates Hypertonicity-Induced Apoptosis By Suppressing Nf Kappa B/Cox-2 In Medullary Interstitial Cells

Effect of activating PKA signaling on dedifferentiation of podocytes in adriamycin-induced nephropathy mice

Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease

MO019: Preclinical Efficacy of Direct AMPK Activation with a Novel Small Molecule–PXL770–For the Treatment of Autosomal Dominant Polycystic Kidney Disease

Activation AMPK in Hypothalamic Paraventricular Nucleus Improves Renovascular Hypertension Through ERK1/2-NF-κB Pathway

HL156A, an AMP-Activated Protein Kinase Activator, Inhibits Cyst Growth in Autosomal Dominant Polycystic Kidney Disease

Abstract 026: Renal Medullary (pro)renin Receptor Mediates Angiotensin II-Induced Hypertension Via Enhancement of Local Renin Response and Renal Medullary Α-Enac Expression

cGMP-selective phosphodiesterase inhibitors stimulate mitochondrial biogenesis and promote recovery from acute kidney injury

Persistent Camp Signaling Via Vasopressin V2 Receptors Imaged in 3d Cultures Using Lightsheet Microscopy

Renal Effects of Combination Phosphodiesterase V Inhibition and Low-Dose B-Type Natriuretic Peptide in Acute Heart Failure: A Randomized Clinical Trial

Imidazo[1,2‐a]pyridine Derivatives as AMPK Activators: Synthesis, Structure–Activity Relationships, and Regulation of Reactive Oxygen Species in Renal Fibroblasts

AMPK couples plasma renin to cellular metabolism by phosphorylation of ACC1

P2Y12 Receptor Localizes in the Renal Collecting Duct and Its Blockade Augments Arginine Vasopressin Action and Alleviates Nephrogenic Diabetes Insipidus

AMPKα, hs-CRP and FcγR in diabetic nephropathy and drug intervention

ULK1-regulated AMP sensing by AMPK and its application for the treatment of chronic kidney disease

HL156A, a novel pharmacological agent with potent adenosine-monophosphate-activated protein kinase (AMPK) activator activity ameliorates renal fibrosis in a rat unilateral ureteral obstruction model

Camp Signaling Prevents Podocyte Apoptosis Via Activation of Protein Kinase A and Mitochondrial Fusion